Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of hydrocortisone replacement therapy in patients with partial cortisol deficiency after traumatic brain injury or subarachnoid hemorrhage on cognitive function.

Detailed Description
-----------------
This is a controlled, randomized, double-blind, placebo-controlled, crossover, interventional study. The benefit of replacement in partial corticotropic failure on brain function (cognition), especially in cases with borderline low cortisol levels after stimulation is unknown. Moreover, since glucocorticoids might affect hGH secretion, the effect of hydrocortisone on hGH secretion reflected by IGF-1 levels will be assessed. If IGF-1 is below 2 SD at the end of the study, hGH secretion will additionally be determined by a GHRH-arginine-test. An improved cognition in TBI and SAH patients with partial corticotropic insufficiency would give a new treatment option in this population which may lead to better quality of life and an enhanced rehabilitation process.

Official Title
-----------------
Phase IV Study to Evaluate the Neuropsychological Effects of Hydrocortisone Substitution in Patients With Partial Adrenal Insufficiency After Traumatic Brain Injury or Subarachnoidal Haemorrhage

Conditions
-----------------
Partial Corticotrope Insufficiency

Intervention / Treatment
-----------------
* Drug: Hydrocortisone
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (male and female) between 18 and 75 years 1 -12 month after TBI or SAH before prescreening Cortisol level 100-180 ng/ml after stimulation with ACTH Written informed consent by patient or a legally accepted representative Exclusion Criteria: Pregnancy and lactation period (during study treatment) Concomitant or previous high-dose therapy with glucocorticoids; previous treatment with glucocorticoids will be accepted, if it has been low dose (i.e. lower than the Cushing threshold) and has been stopped at least 3 months before study participation Suspected or known hypersensitivity to hydrocortisone or any of its components Albumine less than 2,5 g/dl Suspected or known drug or alcohol abuse Planned treatment for thyroid dysfunction or a planned change in established thyroid treatment Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion. Participation in another clinical trial with investigational new drugs Severe medical or psychiatric disease Change of dosage of any other drug which might influence the corticotrope axis or cognitive function (e.g. antidepressive treatment) during the last 3 weeks Oral contraceptives Severe disturbances in articulation, visual faculty or hearing Any elective surgery or medical treatment planned in the observation period Intensive Care treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo/20 mg hydrocortisone<br>Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone | Drug: Hydrocortisone<br>* 20 mg po for 7 days (2 tablets)<br>* Other names: Hydrocortison GALEN 20 mg;Drug: Placebo<br>* 2 tablets po<br>* Other names: P-Tabletten 7 mm Lichtenstein;|
| Active Comparator: 20 mg hydrocortisone/placebo<br>Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo | Drug: Hydrocortisone<br>* 20 mg po for 7 days (2 tablets)<br>* Other names: Hydrocortison GALEN 20 mg;Drug: Placebo<br>* 2 tablets po<br>* Other names: P-Tabletten 7 mm Lichtenstein;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in score of alertness test (TAP)- interindividual differences |  | day -5 to - 0 (before start of study treatment), day 7 (after 7 days treatment with Hydrocortisone or Placebo, day 14 (after 7 days treatment with Hydrocortisone or Placebo) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in score of Alertness Test (TAP) - intraindividual differences |  | day -5 to - 0 (before start of study treatment), day 7 (after 7 days treatment with Hydrocortisone or Placebo, day 14 (after 7 days treatment with Hydrocortisone or Placebo) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neuropsychological effects of hydrocortisone replacement